Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4817-4825

  Douglas, Eleanor J ^a   Fiegler, Heike ^a   Rowan, Andrew ^b   Halford, Sarah ^b   Bicknell, David C ^c   Bodmer, Walter ^c   Tomlinson, Ian P M ^b,d   Carter, Nigel P ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL; CANCER GROWTH; CHROMOSOMAL INSTABILITY; CHROMOSOME 12P; CHROMOSOME 13; CHROMOSOME 15; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME 20; CHROMOSOME 4Q; CHROMOSOME 6; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME LOSS; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENETIC STABILITY; GENOME; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL;

CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; COLORECTAL NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 3142691130     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0328     Document Type: Article

References (58)

1. HMSO. Mortality Statistics. Cause. England and Wales, London: HMSO; 1992.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature (Lond) 1992;359:235-7.
5. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis, Nature (Lond) 1987;327:298-303.
6. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nature Rev Cancer 2001;1:55-67.
7. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature (Lond) 1998;396:643-9.
8. Modrich P. Mechanisms and biological effects of mismatch repair. Annu Rev Genet 1991;25:229-53.
9. Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:335-51.
10. Woodford-Richens KL, Rowan AJ, Gorman P, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci USA 2001;98:9719-23.
11. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash DC) 1992;258:818-21.
12. Ried T, Knutzen R, Steinbeck R, et al. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 1996;15:234-45.
13. Korn WM, Yasutake T, Kuo WL, et al. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;25:82-90.
14. Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 1999;24:306-14.
15. Aragane H, Sakakura C, Nakanishi M, et al. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer 2001;94:623-9.
16. De Angelis PM, Clausen OP, Schjolberg A, Stokke T. Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 1999;80:526-35.
17. Li LS, Kim NG, Kim SH, et al. Chromosomal imbalances in the colorectal carcinomas with microsatellite instability. Am J Pathol 2003;163:1429-36.
18. Snijders AM, Fridlyand J, Mans DA, et al. Shaping of tumor and drug-resistant genomes by instability and selection. Oncogene 2003;22:4370-9.
19. Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 1998;21:172-5.
20. Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994;10:231-43.
21. Kirchhoff M, Gerdes T, Maahr J, et al. Deletions below 10 megabasepairs are detected in comparative genomic hybridization by standard reference intervals. Genes Chromosomes Cancer 1999;25:410-3.
22. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
23. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
24. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6.
25. Fiegler H, Carr P, Douglas EJ, et al. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 2003;36:361-74.
26. Abdel-Rahman WM, Katsura K, Rens W, et al. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci USA 2001;98:2538-43.
27. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits." Proc Natl Acad Sci USA 2000;97:3352-7.
28. Halford S, Sasieni P, Rowan A, et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002;62:53-7.
29. Jain AN, Tokuyasu TA, Snijders AM, et al. Fully automatic quantification of microarray image data. Genome Res 2002;12:325-32.
30. Sieber OM, Heinimann K, Gorman P, et al. Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC. Proc Natl Acad Sci USA 2002;99:16910-5.
31. Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14:85-90.
32. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001;495:56-60.
33. Kamalati T, Jolin HE, Mitchell PJ, et al. Brk, a breast tumor-derived nonreceptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996;271:30956-63.
34. Llor X, Serfas MS, Bie W, et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 1999;5:1767-77.
35. Nourse CR, Mattei MG, Gunning P, Byrne JA. Cloning of a third member of the D52 gene family indicates alternative coding sequence usage in D52-like transcripts. Biochim Biophys Acta 1998;1443:155-68.
36. Anand N, Murthy S, Amann G, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-5.
37. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 2003;44:1-7.
38. Zhang H, Wu J, Meng L, Shou CC. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 2002;8:994-8.
39. Wu H, Li Y, Zhu G, et al. Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma [in Chinese]. Zhonghua Yi Xue Za Zhi 2002;82:708-11.
40. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-52.
41. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash DC) 1996;271:350-3.
42. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6.
43. Page G, Lodige I, Kogel D, Scheidtmann KH. AATF, a novel transcription factor that interacts with Dlk/ZIP kinase and interferes with apoptosis. FEBS Lett 1999;462:187-91.
44. Pei L, Peng Y, Yang Y, et al. PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res 2002;62:5420-4.
45. Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC. Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci 2003;48:266-71.
46. Chen L, O'Bryan JP, Smith HS, Liu E. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. Oncogene 1990;5:1391-5.
47. Mao M, Yu M, Tong JH, et al. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci USA 1996;93:5910-4.
48. Ruppert JM, Kinzler KW, Wong AJ, et al. The GLI-Kruppel family of human genes. Mol Cell Biol 1988;8:3104-13.
49. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993;4:493-540.
50. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
51. Saltzman A, Munro R, Searfoss G, et al. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res 1998;242:244-54.
52. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
53. Won J, Kim DY, La M, et al. Cleavage of 14-3-3 protein by caspase-3 facilitates bad interaction with Bcl-x(L) during apoptosis. J Biol Chem 2003;278:19347-51.
54. Katsuda K, Kataoka M, Uno F, et al. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 2002;21:2108-13.
55. Yilmaz A, Kliche S, Mayr-Beyrle U, Fellbrich G, Waltenberger J. p38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. Biochem Biophys Res Commun 2003;306:730-6.
56. Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002;1:220-6.
57. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science (Wash DC) 2003;301:94-6.
58. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996;87:629-38.